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epression is an incapacitating disorder with a
lifetime prevalence of 16%,
1 with a female-to-male ratio
of about 5:2. Research is beginning to allow us to fully
grasp the complexity of factors—personal,genetic,bio-
logical,societal,and environmental—which are involved.
Several efficient treatments and strategies exist,among
which antidepressant drugs are a main choice.Although
the criteria for choosing the best strategy remain empir-
ical—there is some indication that the efficacy of antide-
pressants is comparable between and within classes—
most patients are best treated with a combination of
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Major depression is believed to be a multifactorial disorder involving predisposing temperament and personality traits,
exposure to traumatic and stressful life events, and biological susceptibility. Depression, both unipolar and bipolar,
is a “phasic” disease. Stressful life events are known to trigger depressive episodes, while their influence seems to
decrease over the course of the illness. This suggests that depression is associated with progressive stress response
abnormalities, possibly linked to impairments of structural plasticity and cellular resilience. It therefore appears cru-
cial to adequately treat depression in the early stages of the illness, in order to prevent morphological and functional
abnormalities. While evidence suggests that a severely depressed patient needs antidepressant drug therapy and that
a non-severely depressed patient may benefit from other approaches (ie, “nonbiological”), little research has been
done on the effectiveness of different treatments for depression. The assertion that the clinical efficacy of antide-
pressants is comparable between the classes and within the classes of those medications may be true from a statisti-
cal viewpoint, but is of limited value in practice. The antidepressant drugs may produce differences in therapeutic
response and tolerability. Among the possible predictors of outcome in depression treatment, those derived from clin-
ical assessment, neuroendocrine investigations, polysomnographic sleep parameters, genetic variables, and brain imag-
ing techniques have been extensively studied. This article also reviews therapeutic strategies used when initial treat-
ment fails, and describes briefly new concepts in antidepressant therapies such as the regulation of disturbances in
circadian rhythms. The treatment of depressive illness does not stop with treatment of acute episodes, and has to be
envisaged as a continuous therapeutic intervention, of which we are still not able to determine the optimal duration
of treatment and the moment that it should be ceased.    
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ing to the course of their illness.
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Schematically, one may categorize the treatment of
depression into three phases: acute, continuation, and
maintenance.
3,4As summarized in Table I,each phase is
defined by specific aims and strategies. Some aspects
remain under discussion,especially those concerning the
appropriate duration of long-term treatment.
The first decision the clinician has to make is whether to
hospitalize a depressed patient or to schedule outpatient
treatment.Hospitalization is indicated when there is a
risk of suicide or homicide associated or not with a severe
depression—in particular with psychotic features— a
notion of “treatment resistance”(supporting in fact the
concept of therapeutic inefficacy or inadequacy,needing
therefore an alternative therapeutic strategy), the
absence of a patient support system,or the need for com-
plementary diagnostic procedures.
Clinical and biological assessment
Depression is both clinically and biologically a heteroge-
neous entity.Typically the course of the disease is recur-
rent—75% of patients experience more than one episode
of major depression within 10 years. Although most
patients recover from major depressive episode, about
50% have an inadequate response to an individual anti-
depressant trial.
5 Moreover, a substantial proportion of
patients (about 10%
6) become chronic (ie,2 years without
clinical remission) which then leads to severe and cogni-
tive functional impairment as well as psychosocial disabil-
ity.
7 Therefore, the assertion that the clinical efficacy of
antidepressants is comparable between the classes and
within the classes of those medications
8 may be true from
a statistical viewpoint but is of limited value in practice.
For a given patient,antidepressant drugs may produce dif-
ferences in therapeutic response and tolerability.
In order to predict outcome,it appears essential to deter-
mine parameters that would rationalize the therapeutic
choice,taking into account not only the clinical features
but also the “biological state”which is a major determi-
nant in the antidepressant response.
Clinical predictors
Typical symptoms of depression include depressed mood,
diminished interest or pleasure (anhedonia),feelings of
worthlessness or inappropriate guilt,decrease in appetite
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Selected abbreviations and acronyms
5-HT serotonin
ACTH adrenocorticotropin
CRH corticotropin-releasing hormone
DA dopamine
HPA axis hypothalamic-pituitary-adrenal axis
NA noradrenaline
SNRI serotonin and noradrenaline reuptake inhibitor
SSRI selective serotonin reuptake inhibitor
TCA tricyclic antidepressant
Table I. Phases of treatment of depression (adapted from refs 3,4).
Aims Duration
Acute Remission of symptoms:
- 50-75% reduction in the baseline level of severity (partial  - 6 to 8 weeks with adequate dose of antidepressant
response): increased risk of relapse and treatment resistance;  - 12 to 16 weeks with psychotherapy
sustained risk of suicide 
- 75-100% improvement or Hamilton Depression Rating 
Scale score ≤ 7 (full response)
- Full remission: full response sustained for 4 weeks
Continuation Stabilize remission and prevent a return of the symptoms  - Approximately 6 months if no reappearence of acute
of the acute phase (ie, relapse) symptoms
- If symptomatic breakthroughs, prolongation for 9 to 12 
months
Maintenance - Recovery  - Discontinuing treatment (single episode) after a stable
- Preventing a new episode (ie, recurrence) recovery period of 6 months 
- Continuing > 1 year (eg, 3 to 5 years, when the risk of 
recurrence is high); lifetime pharmacologic maintenance for 
patients with three or more prior episodes (questionable)and libido,insomnia,and recurrent thoughts of death or
suicide (in about half of patients).Up to 15% of patients
with severe depression die from suicide.
9 Suicidal risk
should be assessed not only at the initiation of the treat-
ment,but repeatedly throughout treatment (typically this
risk is increased during the first 2 weeks of treatment).In
fact,it appears that the risk of suicide attempt does not
differ among antidepressants,but the rate of death from
overdose is higher with tricyclics (owing to their car-
diotoxicity) than with nontricyclics.
10This may have impli-
cations for the choice of an antidepressant for a
depressed patient at risk for suicidal behavior. On the
other hand, about half of suicide victims with major
depression had received inadequate treatment.
11
It has been argued that all subtypes of depressive disor-
ders may be an indication for antidepressants,
12 but the
main “intuitive”criteria for prescribing antidepressants
remains the severity of the depressive symptoms (eg,
Hamilton Depression Rating Scale [HDRS] score >18).
Indeed,some investigators have concluded that there is no
evidence for greater effectiveness of a standard reference
treatment (ie,imipramine plus clinical management) ver-
sus brief psychotherapies (interpersonal therapy,cognitive
behavioral therapy) or placebo plus clinical management
for the less severely depressed and functionally impaired
outpatients.
13 On the other hand,greater depression sever-
ity at baseline generally predicts a poorer response to
pharmacotherapy or psychotherapy.
14,15
Many prospective studies have been published—with
conflicting results—on the predictive value of clinical
variables such as temporal aspects (age at onset,duration
of the disorder, number of recurrences), treatment-
related variables (out- or inpatients, number of prior
treatments, nature of treatment, dosage, duration, and
compliance),demographic characteristics (age,gender),
social and family variables (marital status,social support),
and comorbidity (eg,Axis II personality disorders;Axis
I comorbidity such as anxiety,especially panic disorder
and/or substance and alcohol abuse; Axis III such as
hypothyroidism,diabetes,stroke,coronary artery disease,
Parkinson’s disease, cancer, immunodeficiency syn-
dromes,and chronic pain syndrome [for review see ref
4]).Comorbidity is generally considered to be a factor
contributing to poor treatment response.
However,some clinical features may lead to specific strate-
gies.For example,psychotic depression,representing over
15% of severely depressed patients, generally does not
respond favorably to antidepressant monotherapy.Initial
studies have shown that tricyclic antidepressants (TCAs)
combined with typical antipsychotics have greater efficacy
than TCAs alone.
16 More recently,selective serotonin reup-
take inhibitors (SSRIs) and serotonin and noradrenaline
reuptake inhibitors (SNRIs) combined with typical or
atypical antipsychotics,have demonstrated efficacy in psy-
chotic depression.
17The antipsychotic medication can be
tapered off and stopped when psychotic symptoms have
subsided (generally after 1 to 3 months).Electroconvulsive
therapy (ECT), despite many drawbacks, remains indi-
cated in some “refractory”cases.
18
Bipolar depression also requires specific strategies,since
response to antidepressant treatment is often partial.
Indeed,both TCAs and SSRIs are moderately efficacious
in this population.
19 Moreover, manic switch may occur
(substantially more often with TCAs [approximately 11%]
than SSRIs [both approximately 4%]
20,21).Therefore,it is
suggested to use a mood stabilizer (carbamazepine/oxcar-
bazepine,valproate,lithium carbonate,lamotrigine) as the
first-line therapy at an optimal dose (and drug plasma con-
centration when available) and to add an antidepressant
in case of partial/nonresponse.The recommended period
of mood stabilizer monotherapy is 1 month
4; it is also
expected that the mood stabilizer treatment would prevent
a switch into mania when an antidepressant is added.
Recent trials suggest that SSRIs and SNRIs combined with
atypical antipsychotics are also efficacious (for review see
ref 22).Olanzapine and risperidone,for example,are now
approved for maintenance treatment in bipolar disorder.
Biological predictors
During the past years there has been increased interest
in the identification of biological predictors of outcome
in depression. Among the possible predictors, those
derived from neuroendocrine investigations,polysomno-
graphic sleep parameters, genetic variables, and brain
imaging techniques have been extensively studied.
Neuroendocrine investigations
These predictors can be measured at baseline (ie,after a
sufficient drug-withdrawal period) and/or during the
course of treatment.
The hypothalamic-pituitary-adrenal (HPA) axis in the psy-
chobiology of depression has been widely documented
(for review see ref 23).Increased cortisol secretion,failure
to suppress cortisol in response to dexamethasone—the
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corticotropin (ACTH)/cortisol response to the 
combined dexamethasone/corticotropin-releasing hor-
mone (DEX/CRH) test have been consistently associated
with severe depression.
24-27 It has been hypothesized that
this stress axis overdrive is primarily a reflection of abnor-
mal limbic-hypothalamic activation,with chronic increased
secretion of corticotropin-releasing hormone (CRH) and
consequent excessive adrenal cortisol secretion linked to
impaired negative feedback at the level of the pituitary
corticotroph (ie,decreased type II glucocorticoid receptor
function). The presence of an abnormal DST or
DEX/CRH test indicates the need for a biological treat-
ment,while the initial status of these tests has no predic-
tive value in the choice of given antidepressants.
28 Serial
DST or combined DEX/CRH test monitoring of
depressed patients undergoing drug treatment showed
that normalization typically precedes or coincides with
(rather than follows) clinical recovery,and failure to nor-
malize portends poorly for clinical outcome.
29-31 These
results suggest that lowering HPA activity—via the
restoration of type II glucocorticoid receptor function with
a subsequent re-establishment of HPA axis negative feed-
back—and clinical response are related.
The hypothalamic-pituitary-thyroid (HPT) axis is often
abnormal in depression. The main abnormality is a
chronobiological dysfunction of this axis as reflected by
the decreased mean and amplitude of the 24-hour thyroid-
stimulating hormone (TSH) secretion
32,33 and the blunted
TSH test (ie,difference in ΔΔTSH response between 11 PM
and 8 AM protirelin [TRH] tests) in about 80% of
depressed inpatients.
34When HPT dysregulation is more
pronounced,the 11 PMTRH-TSH test is also abnormal (in
about 40% of patients),while the 8 AMTRH-TSH test is
blunted in only a minority of inpatients (<20%). It has
been suggested
34 that blunted TRH-induced TSH stimula-
tion might be a reflection of downregulation of the thy-
rotropin-releasing hormone (TRH) receptors in the pitu-
itary gland secondary to a prolonged increase in
hypothalamic TRH stimulation.Furthermore,the shift to
higher iodothyronine levels in euthyroid depressed inpa-
tients,both in the morning
35 and in the evening
36 may con-
tribute to the blunting of TSH response to TRH.
37,38The
presence of a blunted TRH test or an abnormal ΔΔTSH
indicates the need for a biological treatment,while the ini-
tial status of these tests has no predictive value in the
choice of given antidepressants.However,patients with the
lowest pretreatment evening TSH secretion (basal and
after 11 PMTRH stimulation) have been found to have the
lowest rate of antidepressant response.
39 The reduced
ΔΔTSH values is a “state”marker of depression since its
normalization is associated with remission.
39 Conversely,
persistence of blunted responses (ie,8 AM-ΔTSH and/or 11
PM-ΔTSH and/or ΔΔTSH) during remission could repre-
sent a “vulnerability”marker of depression.
Investigation of the noradrenergic (NA) system.One of
the most consistently reported abnormal findings in
depression is a blunted growth hormone (GH) response
to acute administration of clonidine, a partial α2-
adrenoreceptor agonist,in drug-free patients.This abnor-
mality suggests subsensitive postsynaptic α2-adrenore-
ceptors at the hypothalamic level, via growth
hormone-releasing hormone release,linked to an erratic
release of norepinephrine.
40 This finding has led to a
reformulation of the original NA depletion hypothesis of
depression into the “noradrenergic dysregulation hypoth-
esis,”
40 which emphasizes a primary subsensitivity or
downregulation in nerve terminal α2-adrenoreceptors,
leading to impaired negative feedback on the presynap-
tic neuron,which in turn may induce a disinhibition of
NA output and exaggerated NA release in response to
any activation of the catecholaminergic system.However,
blunted GH response to clonidine does not appear spe-
cific to depression but rather to the “anxiety spectrum,”
since this blunting has also been observed in generalized
anxiety disorder,
41 panic disorder,
42,43 and social phobia.
44
It has also been argued that deficiencies in noradrener-
gic function could lead to differential response to nora-
drenaline and serotonin reuptake inhibitors.
45 In a study
by Coote et al
46 the decreased GH response,before treat-
ment, was correlated with subsequent good clinical
response to desipramine (a “noradrenergic”antidepres-
sant). In a recent study, Correa et al
47 reported that
amitriptyline,which primarily increases noradrenergic
function, was more efficacious than fluoxetine in
depressed patients showing blunted GH to clonidine at
baseline (amitriptyline is at least 100 times most potent
than fluoxetine in the inhibition of the noradrenaline
transporter 
48).Taken together,these results suggest that
the noradrenergic function might influence response to
antidepressant treatment.
Polysomnographic sleep parameters
Depression is often associated with difficulties in initia-
tion and maintenance of sleep,as well as poor subjective
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between subjective complaints of sleep and objective
measurements,alterations can be observed polysomno-
graphically in approximately 90% of depressed patients
(for review see ref 49).Many of the sleep abnormalities
in depression also occur in other psychiatric disorders.
The most characteristic alterations in the sleep elec-
troencephalogram (EEG) during major depression are a
shortened latency to rapid eye movement (REM) sleep
and an increase in REM density.These changes might
represent vulnerability markers. Recently it has been
reported that the increased REM density was observed
not only in depressed patients,but also in their healthy
relatives who subsequently developed an affective dis-
order.
50 Furthermore,increased REM density has been
found to be predictive for the occurrence of recurrences
in follow-up and has been related to excessive stress hor-
mone response in the DEX/CRH-test (owing to HPA
axis overdrive).
51This suggests that EEG and HPA dis-
turbances may reflect important mechanisms responsi-
ble for causing and maintaining the disease process of
depression.
Antidepressants have class- and compound- specific
effects on polysomnographic profiles.Most antidepres-
sants (eg,TCAs,SSRIs) induce a decrease or suppression
of REM sleep and increase REM sleep onset latency.
52
The decrease in amount of REM sleep appears to be
greatest early in treatment,and gradually diminishes dur-
ing long-term treatment.On the other hand,some anti-
depressants such as bupropion may increase or intensify
REM sleep. Sleep initiation and maintenance are also
affected by antidepressants.Some antidepressants such as
the SSRIs (particularly fluoxetine) and the SNRIs (par-
ticularly venlafaxine
53) may be sleep-disturbing early in
treatment,and some others such as amitriptyline,mianser-
ine,and the newer serotonin (5-HT)2-receptor antagonists
(eg,nefazodone,mirtazapine),are sleep-promoting.This
may be an important clinical goal in some patients.
Generally the sleep of depressed patients (ie,objective
measures,and subjective impression) improves over 3 to
4 weeks of effective antidepressant treatment with most
agents.The new antidepressant agomelatine,a melaton-
ergic MT1/MT2 receptor agonist with 5-HT2c antagonist
properties,
54,55 has shown beneficial effects on sleep in
depressed patients,with reorganization of sleep architec-
ture and without sedative or hangover effects from the
first week of treatment.
56-58 Patients with other sleep dis-
orders such as restless legs syndrome should be identified
before choosing a treatment, as some antidepressants
(such as TCAs,SSRIs) may worsen this syndrome.
Genetic variables
Pharmacogenetics (ie,the variability in drug response and
metabolism due to genetic variants) may explain in part
the heterogeneity in response to antidepressant drugs.
59
Antidepressant targets are primarily the monoaminergic
neurotransmitter systems (eg,5-HT,NA,and to a lesser
extent dopamine [DA]) by inhibiting (more or less specif-
ically) neurotransmitter transporters or receptors,leading
to an increase in synaptic levels of monoamines.
For example,the serotonin transporter (5-HTT) is a tar-
get of SSRIs,SNRIs,and most TCAs.It has been found
that the short (S) allele reduces the transcriptional activ-
ity of the 5-HTT gene promoter,leading to reduced 5-
HTT expression and 5-HT uptake.
60 Patients carrying the
S allele are more vulnerable to stress and depression.
61,62
In a caucasian population, the 5-HTT promoter poly-
morphism seems to play a role in the response to SSRIs:
the S/S genotype has been associated with poor response
to citalopram and fluvoxamine,while the individuals car-
rying at least one L allele were good responders to flu-
voxamine and paroxetine.
63,64 However,in an Asian pop-
ulation, the S/S genotype was associated with good
response to antidepressant treatment,suggesting com-
plex interactions between 5-HTT variants and treatment
response according to the ethnicity of the population
studied.Discrepant results have also been reported con-
cerning other functional gene variants coding for the NA
and DA systems (for review see ref 59).
Concerning the drug-metabolizing enzymes,those of the
cytochrome P-450 (CYP) family are largely involved in
the phamacokinetic/pharmacodynamic variability of the
antidepressants.Inter- and intraindividual differences in
activity of the CYPs are due to genetic variants,but the
CYP activity may be induced or inhibited by some drugs
or environmental factors (for review see refs 65,66).All
the interactions have significant effect on the bioavail-
ability of the antidepressant drugs when such drugs
and/or environmental factors are combined.In some spe-
cific cases (treatment inefficacy,severe adverse effects
[eg,confusion]) CYP genotyping (which is not influenced
by environmental factors and represents a “trait
marker”) and/or phenotyping (which represents a “state
marker”) may be indicated in association with plasma
drug concentration.
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Structural brain imaging studies have revealed abnor-
malities in major depression.Among the most consistent
abnormalities are enlarged lateral ventricles,decreased
size of certain brain structures involved in the modula-
tion of emotional behavior (eg,hippocampus,frontal lobe
volume,basal ganglia,)
67 and increased subcortical white
matter hyperintensity (SCH).
68,69 SCH has been related
to poor treatment response and thus might have some
value in clinical decision-making.
70
Functional brain imaging studies have shown decreased
blood flow and metabolism in the the frontal cortex,tem-
poral cortex, cingulate gyrus, basal ganglia, amygdala,
hippocampus,and thalamus.Older studies had found that
increased activity in the cingulate gyrus at rest was pre-
dictive of a good response to sleep deprivation
71-73 or
treatment with fluoxetine.
74 Abnormalities in regional
cerebral blood flow are at least partly reversed by anti-
depressant treatment including SSRIs,
75 SNRIs (eg,ven-
lafaxine
76),and vagus nerve stimulation.
77
Toward an integrative model of depression:
therapeutic implications
Major depression is believed to be a multifactorial disor-
der including predisposing temperament and personality
traits,exposure to traumatic and stressful life events,and
biological susceptibility. Depression, both unipolar and
bipolar,is characterized by recurrence of mood episodes,
and consequently may be seen as a “phasic” disease.
Stressful life events that involve loss,threat,humiliation,or
defeat are known to trigger depressive episodes,while their
influence seem to decrease over the course of the illness.
78,79
This has suggested that depression is associated with pro-
gressive stress response abnormalities possibly linked to
impairments of structural plasticity and cellular resilience.
80
We will review the kindling hypothesis and the HPA axis
hypothesis of depression,and will describe a recent theory
of the pathogenesis of depressive illness,namely neuro-
plasticity.Furthermore,another promising area of research
in depression,resynchronization of circadian rhythms and
its therapeutic implications will be briefly commented on.
The kindling hypothesis
The primary conceptual framework to some of the phe-
nomena of illness initiation and progression is the “kin-
dling”hypothesis,
81,82 inspired by temporal and develop-
mental similarities between the clinical course of affec-
tive disorders and that of seizure disorders.Kindling is a
form of sensitization of the brain tissue (eg,limbic and
other subcortical areas) leading to functional and struc-
tural alteration, including the induction of gene tran-
scription factors such as c-fos.Induction of c-fos leads to
neurochemical changes at neurotransmitter and recep-
tor levels.
The kindling model proposes that certain types of stres-
sors,repetitively experienced in a predisposed individual,
will lead to mood symptoms of increasing intensity and
duration until a full-blown depressive (or manic episode)
occurs.This model may explain some of the key aspects
of depression: (i) the first lifetime episodes are more
strongly associated with major life stress than are succes-
sive recurrences;(ii) the severity and duration of the non-
treated episodes increase with clinical course (the corol-
lary of this is a possible treatment resistance);and (iii) the
interval between episodes decreases with the duration of
the illness.This hypothesis has nevertheless its limitations,
although has recently regained some interest.
83
The hypothalamic-pituitary-adrenal (HPA) axis, stress,
and depression 
Classically,stress is defined as a threat to homeostasis,to
which the organism,in order to survive,responds with a
large number of adaptive responses implicating the acti-
vation of the sympathetic nervous system and the HPA
axis.Several forebrain structures,including the prefrontal
cortex,hippocampus,amygdala,and septum have been
shown to influence stress responsivity. Synaptic inputs
from several brain regions converge on the paraventric-
ular nucleus in the hypothalamus,which is the final inte-
grator of the stress response.Neurons of this nucleus pro-
duce CRH leading to behavioral activation and to the
secretion of adrenocorticotropin (ACTH) from the ante-
rior pituitary gland.ACTH elicits release of cortisol from
the adrenal cortex. Cortisol inhibits its own release by
inhibiting the secretion and synthesis of ACTH at the
level of the pituitary and of CRH at hypothalamic and
upstream sites.Thus,the HPA system is the key effector
of the stress response,and it has been demonstrated that
chronic exposure to heightened glucocorticoid levels can
lead to permanent changes in the HPA axis.Damage to
the hippocampus,as a result of the reduction in cellular
density and glucocorticoid receptors,impairs the nega-
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tive feedback system that dampens HPA activation.
84
Moreover, clinical and experimental data suggest that
glucocorticoids affect the activity of catecholamine
85,86
and thyroid
87 systems,which have consistently been found
to be dysregulated in depression.
88-90A recent neuroen-
docrine study,conducted in a selected sample of unipo-
lar depressed inpatients with melancholic and psychotic
features,
91 supports a pathophysiological link between
hypercortisolemia and dysregulation of the NA,
dopamine (DA),and HPT systems.
Interestingly,there is accumulating evidence (for review
see ref 92) that TRH is a key central nervous system
(CNS) homeostatic modulator.TRH not only regulates
thyroid axis activity,but owing to its large distribution in
the CNS (especially in limbic-cortical regions) TRH is
also involved in regulation of many neurotransmitters
(eg,NA,DA,5-HT,acethylcholine).In depression TRH
hypersecretion (as reflected by TRH-TSH abnormalities)
may be regarded as a compensatory mechanism in order
to correct neurotransmitter alterations (particularly those
involving 5-HT and NA systems
91,93).TRH also modulates
a variety of vegetative and chronobiological functions
and has a role in the adaptative response to stress.The
homeostatic properties are further suggested by the fact
that TRH is an anticonvulsifiant (TRH is stimulated by
kindling and seizures and TRH inhibits seizure),analep-
tic (only when the organism is sedated),promnesic (TRH
increases learning and memory) and antiapoptotic.
Finally,previous studies have shown that TRH has anti-
depressant effects
94,95 but owing to its short half-life
(about 3 minutes) and the uncertain ability to the pep-
tide to gain access to the CNS after peripheral adminis-
tration inconsistent findings have been reported with
native TRH.
HPA axis and neural plasticity: implications for 
antidepressant treatment
Recent studies have shown that chronic or cumulated
stress induce neuronal atrophy in some vulnerable brain
structures such as the hippocampus (atrophy of CA3
pyramidal neurons,decreased number and length of api-
cal dendrites) and decreased neurogenesis (for reviews
see refs 84,96).Reduced volume has been associated with
duration of depression and cognitive difficulties such as
impairment list learning and a specific recollection task.
97
The relationship between hippocampus volume and ill-
ness duration further suggests that it is possible to stop
or delay progression of the morphological changes asso-
ciated with depression. Indeed, it has been shown that
antidepressant treatment (eg,tianeptine,TCAs,SSRIs,
ECT) increases neural plasticity at the level of neuroge-
nesis (by increasing the number of newborn neurons con-
tributing to reverse hippocampal atrophy),signal trans-
duction and gene expression (for review see refs 84,96).
Since decreased hippocampal volume has been corre-
lated with duration of depressive illness
97,98 and CRH has
a critical role in long-term effects of early-life stress on
hippocampal integrity and function
99 it is suggested that
chronic hypercortisolemia associated with alterations in
neuroplasticity and neurogenesis may underlie the vul-
nerability to subsequent depressive episodes.
It appears therefore crucial to adequately treat depres-
sion in the early stages of illness in order to prevent mor-
phological and functional abnormalities.
Circadian rhythms and depression
Depressive disorder is characterized by a profound dis-
turbance of circadian rhythms,mainly characterized by a
reduction in the amplitude.
100This flattened amplitude has
been reported for temperature,TSH,plasma melatonin,
cortisol,and motor activity.Most importantly,in depres-
sion,the deregulation of circadian rhythms is reflected in
disturbed sleep-wake cycles.
49 It has been shown that cir-
cadian rhythms are normalized during remission and that
unavoidable disturbances in circadian rhythms can trigger
depressive episodes in humans.
101This could suggest that
circadian abnormalities may play a role in the pathogene-
sis of depression.Agomelatine,a melatonergic receptor
agonist and 5HT2c receptor antagonist, resynchronizes
human circadian rhythms in healthy volunteers
102,103 and
depressed patients,
57 and has shown a powerful antide-
pressant efficacy in major depressive disorder.
104-106 The
wide prevalence of circadian dysfunction in depression
and the improvement of depression after treatment with
this new antidepressant add to the suggestion that the cir-
cadian abnormalities may be part of the core of depres-
sion,rather than a consequence of the illness.
Acute treatment
The choice of the antidepressant treatment (Table II)
needs to be tailored to the particular patient's medical
condition and personal preferences.Evidence suggests
that a severely depressed patient needs antidepressantdrug therapy, while a while a nonsevere patient with
major depression may benefit from other approaches (ie,
“nonbiological”).However,little research has been done
on the effectiveness of different treatments for depres-
sion,and the fact that clinicians can individually predict
the evolution of patients has been rarely studied.
107 In
some cases specific treatment may be recommended.For
example,bright light (BL) treatment is indicated in sea-
sonal affective disorder and depression during preg-
nancy.
108The probable mechanisms of action of BL treat-
ment are synchronization of biological rhythms and
increase in serotonin transmission in the human brain.In
general this treatment is safe and well tolerated.
109
How and when should antidepressants be prescribed?
Optimal treatment starts with appropriate patient edu-
cation about the nature of the illness and the nature of
the proposed treatment. Specific psychological treat-
ments are effective for major depression,with greatest
evidence for mild-to-moderate depression,while no spe-
cific psychotherapy emerges as being superior to others.
In moderate depression the decision to prescribe an anti-
depressant can be taken over the course of a few weeks.
In severely or recurrently depressed patients,the use of
antidepressants is recommended,since the neurobiolog-
ical substrate is too severely disturbed to be responsive
to psychotherapy alone.
110
Given the supposed equivalence of therapeutic effect,the
choice of antidepressant drug is based on the type of
symptomatology as well as severity of the symptoms,
avoidance of side effects (eg,sedation,weight gain,sex-
ual dysfunction),presence of comorbid psychiatric and/or
somatic disorders,prior positive and/or negative response
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Table II. Specific depression subscales derived from the HAM-D by the microanalytic approach. SRI, Serotonin reuptake inhibitor; NRI, Noradrenaline reup-
take inhibitor; DRI, Dopamine reuptake inhibitor; MAOI, monoamine oxidase inhibitor
1. ANTIDEPRESSANT DRUGS
• Tricyclic and tetracyclic antidepressants (TCAs)
clomipramine (SRI>>NRI); amitriptyline (SRI>NRI)
imipramine, doxepine, amoxapine (NRI=SRI) 
desipramine (NRI>SRI))
maprotiline (NRI)
• Selective serotonin reuptake inhibitors (SSRIs)
citalopram, escitalopram
fluoxetine (also NRI, and weak D2 receptor blocker)
fluvoxamine (also weak NRI, and melatonin agonist)
paroxetine (also NRI>>DaRI)
sertraline (also DaRI>>NRI)
• Selective serontonin and noradrenaline reuptake 
inhibitors (SNRIs)
venlafaxine, milnacipran, duloxetine
• Noradrenaline α2 receptor antagonist and serotonin 5-HT2
receptor antagonist
mianserine, mirtazapine
• Serotonin (5-HT2) receptor antagonists
trazodone, nefazodone
• Noradrenaline reuptake inhibitor
reboxetine
• Dopamine reuptake inhibitors
bupropion (also weak NI), methylphenydate
• Monoamine oxidase inhibitors (MAOIs)
irreversible and nonselective: iproniazide
reversible and selective: 
MAOI-A (moclobemide, toloxatone)
MAOI-B (selegiline)
• Melatoninergic (MT1/2) receptor agonist and selective 
5-HT2 receptor antagonist
agomelatine
• Others
Tianeptine
herbal medicine: hypericum perforatum (St. John's wort)
amino acid derivative S-adenosylmethionine (SAM-e)
tryptophan and 5 hydroxytryptophan dietary supplements
2. MOOD STABILIZERS
• Lithium salts 
• Antiepileptics
carabazepine/oxcarbazepine, sodium valproate/divalproate/ 
valpromide, lamotrigine 
3. “NONCHEMICAL” THERAPIES
• Sleep deprivation (total: all night; partial: second half 
of the night)
• Light therapy
• Electroconvulsive therapy
• Magnetic stimulation
• Vagus nerve stimulation 
• Deep brain stimulation
4. PSYCHOTHERAPY
• Cognitive therapy
• Interpersonal psychotherapy
• Problem-solving therapy
• Psychodynamic-interpersonal psychotherapy
• Psychoanalytic oriented psychotherapy(and tolerability/adverse effects) to a given antidepres-
sant.Other considerations are the contraindications and
potential toxicity of the drug and,to a lesser degree,its
cost.Moreover,patient preference—after being informed
about the benefit-risk ratio—may be expected to
enhance compliance.
It has been suggested that SSRIs are more effective than
primarily noradrenergic antidepressants (eg,maprotiline)
in reducing irritability/aggression and anxious symp-
toms.
111-114 On the other hand,severely depressed patients
with psychomotor retardation respond more favorably
to treatment with noradrenergic antidepressants than
with SSRIs.
115 Some studies
116 suggest that monoamine
oxidase inhibitors (MAOIs) are highly effective in out-
patients with “atypical depression” (characterized by
fatigue, excessive need for sleep, increased appetite/
weight gain,and rejection sensitivity).However,given the
dietary restriction needed and the numerous interactions
with other drugs,MAOIs remain a second-line treatment
in this group of patients.
Drug selection
Evidence-based guidelines
117,118 suggest that newer anti-
depressants,mainly SSRIs,should be prescribed in mildly
and moderately depressed patients, and TCAs or ven-
lafaxine in severely depressed patients. Controversy
exists about whether the newer antidepressants are as
effective as the TCAs.Some meta-analyses,
119-122 but not
all,
123 indicate that TCAs (eg, amitriptyline,
clomipramine) and venlafaxine (at a dose of 150 mg or
greater) are more effective than SSRIs (citalopram,
paroxetine) or moclobemide in severely depressed inpa-
tients.Although this is not unanimously admitted, the
efficacy of TCAs is related to the administered dose (a
dose of 150 mg/day is more effective than 75 mg/day in
severe depression).However,owing to their anticholin-
ergic adverse effects (such as dry mouth, constipation,
blurred vision,impaired concentration,and confusion)
TCAs are usually prescribed below recommended doses
(for review see ref 4).Thus,in order to minimize adverse
effects, TCAs have to be started at a low dose and
increased gradually (every 3 to 7 days);the delayed clin-
ical response also makes it difficult to establish the opti-
mal dose quickly (TCAs take 2 to 4 weeks before an anti-
depressant effect is evident).
On the other hand,SSRIs and newer antidepressants are
better tolerated than TCAs and are safer in overdose.
Moreover,their dose formulation tends to ensure ade-
quate dosing, and they can be administered at the rec-
ommended dose after a few days of treatment at a lower
dose.The adverse reactions associated with the SSRIs
(eg,nausea,diarrhea,anxiety,agitation,sexual dysfunc-
tion,insomnia,and anorexia) may also occur with SNRIs.
Some drugs have specific adverse effects,such as hyper-
tension with venlafaxine and agranulocytosis with
mianserin. It is noteworthy that mirtazapine, induce
weight gain.
New treatment options such as agomelatine will have to
be taken into consideration,once available.
Short-term outcome
It is important to review patients regularly (usually
weekly for the first 4 to 6 weeks) to monitor response,
compliance, side effects with treatment, and suicidal
ideation.Adverse effects are often dose-dependent,and
a dose reduction may alleviate the problem.Moreover,
tolerance occurs for many of the acute adverse effects of
the antidepressants, probably as a result of receptor
downregulation.For this reason,the dose can be gradu-
ally re-escalated,if needed for optimal efficacy,without
the adverse effect necessarily recurring. If there is no
response (< 25% improvement) after 3 weeks it is possi-
ble to increase the dose, while in case of a partial
response,one could wait another 2 weeks before increas-
ing the dose.
124
What are the options in case of nonresponse?
When a patient does not respond to the first-choice anti-
depressant at an adequate dose, three strategies exist:
increasing the dose of the antidepressant, switching to
another antidepressant,or combining several drugs.
Increasing the dose of the initial antidepressant,
118 although
not recommended by all authors, seems a logical step,
since there is wide interindividual variability in plasma
concentration of antidepressants.Checking plasma con-
centrations of the antidepressant (target ranges are avail-
able for most drugs) and the parent compound/metabo-
lite ratio may be helpful to evaluate the metabolite state
and compliance of the patient.
125 For example,norfluox-
etine is a more selective and more potent 5-HT reuptake
inhibitor than fluoxetine (the parent compound) and has
an extremely long half-life (7 to 15 compared with 1 to 3
days).Thus,the metabolite plays an important role for
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2C9 polymorphisms contribute to the interindividual
variability in fluoxetine and norfluoxetine pharmacoki-
netics at steady-state.
126 While some studies found no
advantage of increasing the dose of fluoxetine (for
review see ref 127), Fava and al
128 have reported a bet-
ter outcome with 60 mg/day of fluoxetine in poor respon-
ders to 20 mg/day for 8 weeks.
Venlafaxine has a dual profile,predominantly serotonin
reuptake inhibitor (SRI) at low doses (≤ 75 mg/day) and
noradrenaline reuptake inhibitor (NRI) at higher doses
(the maximum recommended dose is 375 mg/day).
Interindividual variability has been reported with ven-
lafaxine and its main active metabolite, O-desmethyl-
venlafaxine—which also inhibits 5-HT and NA,and has
comparable therapeutic activity to that of the parent
drug.
129 It has been found,but not by all investigators,that
there is a superior effect on depression of higher dose
compared with a lower dose (but with more frequent
adverse effects).
130 Two studies to date have used ven-
lafaxine above the maximum recommended dose (450 to
600 mg/day) in treatment-resistant depression and both
have shown clinical improvement.
131,132 The tolerability
was good (1 transient elevated blood pressure on 14
patients studied).
If it is decided to switch treatment,a drug with a different
or broader mechanism of action should preferably be
chosen.It may be necessary to have a drug-free interval
before starting the new treatment to avoid drug interac-
tions.Irreversible and nonselective monoamine oxidase
inhibitors should be used only in special cases because of
their potentially severe adverse effects.
Combining several drugs
The drugs most often added to antidepressant therapy are
lithium,tri-iodothyronine,or,for patients receiving SSRIs,
a compound acting on the NA and/or DA system.
However, adding another antidepressant to the existing
regimen may increase the risk of drug interactions (ven-
lafaxine, SSRIs, or TCAs should not be combined with
IMAOs, and fluoxetine should not been combined with
TCAs).For nonresponders to SSRIs,buspirone/gepirone
(both are 5-HT1A receptor agonists) or pindolol (a 5-HT1A
receptor antagonist) have been used as adjunctive med-
ication. The presumed mechanism of pindolol involves
interruption in the short-loop negative feedback system,
allowing for an increase in synaptic concentrations of 5-HT.
The use of mood stabilizers is well documented in unipo-
lar and bipolar patients (especially lithium in TCAs non-
responders),and two modalities of response have been
described: one group responds during the first week,
while the second responds after a delay of 4 to 6 weeks
(for review see ref 133).The dose of lithium used in this
strategy (ie,450 to 600 mg/day) is generally lower than
that used for the treatment of acute mania or prophylaxis
of bipolar disorder.Similarly,plasma lithium levels are
lower in the range of 0.4 to 0.8 mEq/L.However the risks
associated with lithium augmentation compared with
that of switching antidepressant drugs needs to be
weighted. Concerning the antiepileptic drugs (such as
carbamazepine/oxcarbazepine,valproate,lamotrigine)
their efficacy as adjuvant therapy has been demonstrated
in bipolar patients (especially in rapid-cyclers).
Thyroid hormones are useful in euthyroid patients for
converting nonresponders into responders. It has been
assumed that tri-iodothyronine (T3) would be preferen-
tially indicated in unipolar patients (a 25-µg to 37.5-µg
daily dose accelerates the time of response to antide-
pressants), while thyroxine (T4) combined with lithium
would be useful in the prevention of mood episodes in
bipolar patients (however the daily dose is generally
high, about 200 to 400 µg, and this may lead to possible
adverse effects [thyrotoxicosis]).
Dopamine agonists such as bromocriptine, pergolide,
pramipexole,and ropinirole have been used with promis-
ing results as adjuvant to antidepressants especially in
bipolar patients.
134 These agonists are also useful in
depressed patients with Parkinson’s disease and in
patients with restless legs syndrome.
Atypical antipsychotics such as risperidone,
135 olanzap-
ine,
136 and aripiprazole
137 may also be useful as adjunctive
medication in nonpsychotic treatment-resistant patients.
Psychostimulants such as d-amphetamine, methyl-
phenidate,and modafinil added to antidepressants have
also been found to be effective in resistant depres-
sion.
138,139
Electroconvulsive therapy (ECT) remains an option for
resistant depression,although there is only a weak possi-
bility that a given patient will respond to ECT if he or she
has previously failed to respond to pharmacotherapy.
140
Transcranial magnetic stimulation (which involves the
depolarization of neurons in a localized area of the brain
by applying a powerful magnetic field in rapid flux),
vagus nerve stimulation,and deep brain stimulation have
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141The efficacy of
these approaches is promising,but needs further confir-
mation.
Chronotherapeutics such as wake therapy—single or
repeated sleep deprivation, total (all night) or partial
(second half of the night)—and light therapy have been
proposed as adjuvant to conventional antidepressants in
unipolar patients, or lithium in bipolar patients (for
review see ref 142).
“Antiglucocorticoid” treatments have been proposed,
assuming that cortisol-lowering treatments may be of
clinical benefit in patients refractory to traditional anti-
depressants (for review see refs 143,144).Ketoconazole,
which inhibits cortisol biosynthesis,and acts at the recep-
tor level as a glucocorticoid antagonist,has led to mixed
results:some authors have found antidepressant proper-
ties,while others,despite the inhibition of cortisol,found
only a weak impact on depression.Moreover,the numer-
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Figure 1. Major depression is a multifactorial disorder including predisposing temperament and personality traits, exposure to traumatic and stress-
ful life events and biological susceptibility. The kindling/sensitization hypothesis may explain some of the key aspects of depression: (i)
the first lifetime episodes are more strongly associated with major life stress than are successive recurrences, (ii) the severity and dura-
tion of the nontreated episodes increase with clinical course, and (iii) the interval between episodes decreases with the duration of the
illness. Damage to the hippocampus, as a result of the reduction in cellular density and glucocorticoid receptors, impairs the negative
feedback system that dampens HPA activation. Since decreased hippocampal volume has been correlated with duration of depressive
illness and CRH has a critical role in long-term effects of early-life stress on hippocampal integrity and function, it has been suggested
that chronic hypercortisolemia, associated with alterations in neuroplasticity and neurogenesis, may underlie the vulnerability to sub-
sequent depressive episode. On the other hand, hypercortisolemia may underlie dysregulation of the noradrenaline, dopamine, sero-
tonin, and acethylcholine systems. TRH is a key central nervous system homeostatic modulator. In depression, TRH hypersecretion may
be regarded as a compensatory mechanism in order to correct neurotransmitter alterations (especially those involving the serotonin and
catecholamine systems). HPT, hypothalamic-pituitary-adrenal; CRH, corticotropin-releasing hormone; Cort, cortex; Hipp, hippocampus;
NA, noradrenaline; TRH, thyrotropin-releasing hormone.ous side effects of ketoconazole (including hepatotoxic-
ity) mandate frequent laboratory monitoring.
Mifepristone (RU-486),a potent glucocorticoid and prog-
esterone receptor antagonist, may be effective in the
treatment of psychotic and bipolar depression and may
re-regulate the HPA axis.
145 CRH1 receptor antagonists
have therapeutic potential in disorders that involve
excessive CRH activity
146 and some are currently under
investigation as antidepressants (eg, antalarmin; CP-
154,526;CP-36,311;GW876008;SSR125543;DMP 696;
ONO-2333Ms;JNJ-19567470;R121919).
147
Conclusion
The treatments of depressive states are based on ratio-
nal approaches involving the understanding of the patho-
physiogenetic mechanisms and the mechanisms of action
of the therapeutics.The noninversion of the mood has to
be considered as therapeutic failure:the rule is to obtain
the cessation of depressive symptoms and then the recov-
ery from the episode.
Of course,the symptoms are cured but not necessary the
illness; and the problem of eventual recurrence is still
present.
The measures to prevent relapses require:
• On the one hand,the perfect understanding of patho-
physiogenesis of depressive illness,which is something
we are not always able to do,
• On the other hand, the use of chronic treatments for
depression,which can be envisaged only if therapeutics
having few or no side effects are available,and these
need to be specifie.They can be normothymic drugs,
but their side affects are not negligible.They can be
antidepressant drugs;most of these have significant side
effects.The use of agomelatine,a melatoninergic ago-
nist with 5HT2c antagonist properties,can be empha-
sized,since this new antidepressant has been shown in
long-term therapy to have antidepressant efficacy
accompanied by good tolerance. In the more or less
near future, products still in development (CRH1
receptor antagonists,TRH analogs) may be available,
if they prove to be efficacious in clinical trials in
depressed patients.
The treatment of depressive illness does not stop with
treatment of acute episodes,and has to be envisaged as
a continuous treatment;of which,for the moment,we are
still not able to determine the appropriate duration and
the time of treatment cessation. ❏
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Tratamientos en la depresión
Se cree que la depresión mayor es un trastorno mul-
tifactorial que involucra el temperamento y los ras-
gos de personalidad como predisponentes, la exposi-
ción a acontecimientos vitales estresante y a sucesos
traumáticos, y la susceptibilidad biológica. Tanto la
depresión unipolar como la bipolar son enfermeda-
des “fásicas”. Los acontecimientos vitales estresantes
pueden gatillar episodios depresivos, y su influencia
parece decrecer a lo largo del curso de la enferme-
dad. Esto sugiere que la depresión se asocia con anor-
malidades progresivas en la respuesta de estrés, lo
que posiblemente se relaciona con deterioros de la
plasticidad estructural y de la resiliencia celular. Por lo
tanto, parece crucial tratar adecuadamente la depre-
sión en las etapas precoces de la enfermedad para
prevenir las alteraciones morfológicas y funcionales.
Mientras la evidencia sugiere que un paciente con
una depresión grave necesita fármacos antidepresi-
vos y que un paciente con una depresión de menor
gravedad puede beneficiarse con otras estrategias (es
decir. “no farmacológicas”), se ha realizado poca
investigación sobre la eficacia de los diferentes trata-
mientos para la depresión. La afirmación que señala
que la eficacia clínica de los antidepresivos es com-
parable entre las clases y dentro de las clases de estos
medicamentos puede ser cierta desde un punto de
vista estadístico, pero tiene un valor limitado en la
práctica. Los antidepresivos pueden producir dife-
rencias en la respuesta terapéutica y en la tolerabili-
dad. Entre los posibles predictores de evolución en el
tratamiento de la depresión se han estudiado exten-
samente aquéllos que derivan de la evaluación clínica,
de las investigaciones neuroendocrinas, de los pará-
metros de polisomnografía del sueño, de las variables
genéticas y de las técnicas de imágenes cerebrales.
Este artículo también revisa las estrategias terapéuti-
cas utilizadas cuando fracasa el tratamiento inicial y
describe brevemente los nuevos conceptos en las
terapias antidepresivas como la regulación de las alte-
raciones en el ritmo circadiano. El tratamiento de la
enfermedad depresiva no finaliza con la terapia de
los episodios agudos, y debe ser visualizado como una
intervención terapéutica continua, acerca de la cual
aun no estamos en condiciones de determinar la
duración óptima del tratamiento, ni el momento en
que éste debe finalizar.  
Traitements de la dépression
La dépression majeure est considérée comme un
trouble multifactoriel associant un tempérament
prédisposé et certains traits de personnalité, une
exposition à des événements de vie traumatisants
et stressants et une sensibilité biologique. La
dépression, à la fois unipolaire et bipolaire, est une
maladie « phasique ». Les événements de vie stres-
sants sont connus pour déclencher les épisodes
dépressifs, alors que leur influence semble diminuer
au cours de la maladie. Ceci suggère que la dépres-
sion est associée à des anomalies de réponse pro-
gressive au stress, probablement liées à des troubles
de plasticité structurale et de résilience cellulaire. Il
apparaît donc crucial de traiter la dépression de
façon adéquate aux stades précoces de la maladie
pour éviter les altérations morphologiques et fonc-
tionnelles. Peu de recherches ont été faites sur l’ef-
ficacité des différents traitements pour la dépres-
sion, alors que des preuves suggèrent qu’un patient
sévèrement déprimé a besoin d’un traitement anti-
dépresseur tandis que celui dont la dépression est
moindre peut bénéficier d’autres approches (par ex.
« non biologiques »). L’affirmation que l’efficacité
clinique des antidépresseurs est comparable entre
les classes et dans les classes de ces médicaments
peut être vraie d’un point de vue statistique, mais
pas en pratique. Les réponses thérapeutiques et de
tolérance aux antidépresseurs sont différentes.
L’évaluation clinique, les investigations neuroen-
docriniennes, les paramètres polysomnographiques
du sommeil, les variables génétiques et les tech-
niques d’imagerie cérébrale ont été largement étu-
diés parmi les indices possibles d’évolution des anti-
dépresseurs. Cet article passe aussi en revue les
stratégies thérapeutiques utilisées en cas d’échec
du traitement initial et décrit rapidement les nou-
veautés concernant les antidépresseurs telles que la
régulation des troubles du rythme circadien. Le trai-
tement de la dépression ne s’arrête pas avec le trai-
tement des épisodes aigus et doit être envisagé
comme un traitement continu, pour lequel la durée
optimale et le moment de l’arrêt ne peuvent pas
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